Xilio Therapeutics Q2 2026: $136M in Cash, Narrower Loss, and FDA Green Light for XTX501

summarizeSummary

Xilio Therapeutics narrowed its Q2 loss, extended its cash runway into early 2028, and secured FDA clearance to start clinical trials for its lead candidate, XTX501.

check_boxKey Events · Earnings and Guidance · XLO

• Cash Runway Extended into Early 2028

  With $136.0M in cash and equivalents as of June 30, 2026, plus a $6.0M AbbVie milestone collected in Q3, operations are funded into early 2028, excluding any potential warrant proceeds.

• Net Loss Narrows Sharply

  The Q2 net loss fell to $6.4M from $15.8M in the prior-year period, thanks to a jump in collaboration revenue to $18.7M from $8.1M and a modest decline in operating expenses.

• FDA Clears IND for XTX501

  The FDA cleared the investigational new drug application for XTX501, a bispecific PD-1/masked IL-2; Phase 1 dosing in metastatic NSCLC and solid tumors is expected to begin in the second half of 2026.

• ATM Sales Add Modest Dilution

  During Q2, the company sold 592,300 shares at a weighted average price of $7.76, generating $4.6M in gross proceeds under its at-the-market facility.

auto_awesomeAnalysis · XLO · Life Sciences

Xilio's second-quarter results underscore a sharp improvement in financial health, with the net loss shrinking to $6.4M from $15.8M a year ago, fueled by $18.7M in collaboration revenue tied to milestones from AbbVie and Gilead. The $136M cash position, supplemented by a $6M milestone received in Q3, pushes the runway into early 2028 — a vital buffer for a pre-revenue biotech. On the pipeline front, the FDA cleared the IND for XTX501, the lead bispecific, and dosing is on track to begin in the second half of 2026. Modest dilution came from $4.6M in stock sold through the ATM. For a company with a $60M market cap, the combination of a fortified balance sheet, advancing pipeline, and lower cash burn marks a meaningful update.